ORIC
Income statement / Annual
Last year (2024), ORIC Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, ORIC Pharmaceuticals, Inc.'s net income was -$127.85 M.
See ORIC Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$1.03 M
|
$966,000.00
|
$897,000.00
|
$970,000.00
|
$1.00 M
|
$900,000.00
|
$900,000.00
|
| Gross Profit |
$0.00
|
-$1.03 M
|
-$966,000.00
|
-$897,000.00
|
-$970,000.00
|
-$1.00 M
|
-$900,000.00
|
-$900,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$114.07 M
|
$85.17 M
|
$61.68 M
|
$56.86 M
|
$35.92 M
|
$22.84 M
|
$19.03 M
|
$19.13 M
|
| General & Administrative Expenses |
$28.82 M
|
$25.61 M
|
$25.09 M
|
$22.01 M
|
$13.42 M
|
$5.73 M
|
$3.35 M
|
$3.42 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$900,000.00
|
| Selling, General & Administrative Expenses |
$28.82 M
|
$25.61 M
|
$25.09 M
|
$22.01 M
|
$13.42 M
|
$5.73 M
|
$3.35 M
|
$2.52 M
|
| Other Expenses |
$0.00
|
$0.00
|
$5.00 M
|
$15,000.00
|
$177,000.00
|
$289,000.00
|
$233,000.00
|
$0.00
|
| Operating Expenses |
$142.90 M
|
$110.78 M
|
$86.77 M
|
$78.87 M
|
$49.34 M
|
$28.57 M
|
$22.37 M
|
$21.64 M
|
| Cost And Expenses |
$0.00
|
$110.78 M
|
$86.77 M
|
$78.87 M
|
$49.34 M
|
$28.57 M
|
$22.37 M
|
$22.54 M
|
| Interest Income |
$0.00
|
$10.08 M
|
$2.65 M
|
$141,000.00
|
$306,000.00
|
$1.40 M
|
$775,000.00
|
$251,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2.65 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.03 M
|
$966,000.00
|
$897,000.00
|
$970,000.00
|
$1.00 M
|
$900,000.00
|
$900,000.00
|
| EBITDA |
-$142.90 M |
-$109.75 M |
-$91.77 M |
-$77.97 M |
-$74.19 M |
-$27.54 M |
-$20.46 M |
-$21.13 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$15.05 M
|
$10.08 M
|
$2.65 M
|
$156,000.00
|
$483,000.00
|
$1.69 M
|
$1.01 M
|
$512,000.00
|
| Income Before Tax |
-$127.85 M
|
-$100.70 M
|
-$89.12 M
|
-$78.72 M
|
-$73.70 M
|
-$26.88 M
|
-$21.36 M
|
-$22.03 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$2.36 M
|
-$1.04 M
|
$23.57 M
|
-$1.40 M
|
-$1.01 M
|
$0.00
|
| Net Income |
-$127.85 M
|
-$100.70 M
|
-$91.48 M
|
-$77.68 M
|
-$97.27 M
|
-$25.49 M
|
-$21.36 M
|
-$22.03 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.83 |
-1.96 |
-2.31 |
-2.05 |
-4.43 |
-0.85 |
-1.12 |
-0.74 |
| EPS Diluted |
-1.83 |
-1.96 |
-2.31 |
-2.05 |
-4.43 |
-0.85 |
-1.12 |
-0.74 |
| Weighted Average Shares Out |
$69.73 M
|
$51.45 M
|
$39.66 M
|
$37.95 M
|
$21.94 M
|
$29.90 M
|
$19.14 M
|
$29.90 M
|
| Weighted Average Shares Out Diluted |
$69.73 M
|
$51.45 M
|
$39.66 M
|
$37.95 M
|
$21.94 M
|
$29.90 M
|
$19.14 M
|
$29.90 M
|
| Link |
|
|
|
|
|
|
|
|
